Frontline ponatinib plus hyper-CVAD over imatinib in adults with Ph-positive acute lymphoblastic leukemia: real-world efficacy and risks of early ponatinib dose reduction

Key Points

• To evaluate the efficacy of ponatinib combined with hyper-CVAD compared to imatinib in treating adults with Ph-positive acute lymphoblastic leukemia.
• Comparison of ponatinib plus hyper-CVAD therapy against imatinib in a real-world setting.
• Assessment of early dose reduction impacts on treatment outcomes.
• Analysis focused on patient responses and risks associated with each treatment option.
• Ponatinib plus hyper-CVAD demonstrated improved efficacy compared to imatinib.
• Early dose reductions of ponatinib were observed to impact treatment effectiveness.
• Risks associated with dose reductions were documented, emphasizing careful management.